These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16026845)

  • 1. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
    Deogaonkar M; Subramanian T
    Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Cenci MA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Understanding and treating levodopa-induced dyskinesias].
    Hadj Tahar A; Bédard PJ
    Tunis Med; 1998 Dec; 76(12):437-47. PubMed ID: 10093483
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
    Picconi B; Calabresi P
    Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease--Part 2: Treatment of motor symptoms.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 11. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.
    Linazasoro G
    Trends Pharmacol Sci; 2005 Aug; 26(8):391-7. PubMed ID: 16009432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
    Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
    Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
    Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
    Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
    Linazasoro G
    Neurologia; 2001 Jan; 16(1):17-29. PubMed ID: 11234658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current developments in the long-term therapy of Parkinson syndrome].
    Ludin HP
    Schweiz Rundsch Med Prax; 1992 Nov; 81(48):1458-60. PubMed ID: 1448642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.